
Final results of first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301)

BACKGROUND

- CRC 3rd most common cancer Incidence: 1.8 million Annual deaths: 880,000¹
- 5-FU remains the cornerstone of treatment for CRC, despite having several limitations
 - Rapidly degraded by DPD²
 - Short plasma half-life (8-14 mins)³ necessitates prolonged (46 hour) infusions
 - Generation of toxic catabolites such as FBAL and FUTP
- Cell entry requires nucleoside transporters
- Complex enzymatic activation

NUC-3373 bypasses the key cancer resistance pathways associated with 5-FU



NUC-3373: A targeted inhibitor of TS

- ProTide transformation of FUDR-MP^{4,5,} the active anti-cancer metabolite of 5-FU • Resistant to breakdown by DPD
- Able to enter cells independently of nucleoside transporters
- Low levels of toxic catabolites (FBAL, FUTP)
- Generates high levels of FUDR-MP⁶, which binds to TS
- Causes an imbalance in the nucleotide pool leading to DNA damage and cell death
- Induces ER stress and DAMP release leading to immunogenic cell death⁷⁻⁹

NuTide:301

- Phase I, two part, dose-escalation study of NUC-3373 in patients with advanced solid tumours
- Study conducted at 3 UK centres between Jan 2016 and Feb 2021

Key eligibility criteria

- Patients aged ≥18 years with any solid tumour not amenable to standard therapy, refractory to standard therapy or for which no standard therapy exists
- ECOG PS 0-2 Measurable or evaluable disease per RECIST 1.1
- Adequate bone marrow, hepatic and renal function LVEF \geq 50%
- Negative pregnancy test for females of childbearing age
- No Intercurrent illness
- No residual toxicities >grade 1
- **PART I NUC-3373** (125 mg/m² - 3250 mg/m²) **Primary Endpoints:** IV infusion on days 1, 8, 15 Establish NUC-3373 & 22 of a 28-day cycle (Q1W RP2D & schedule Secondary Endpoints: Safety & tolerability, Anti-**PART II – NUC-3373** tumour activity, PK 500 mg/m² - 2500 mg/m² PD and others infusion on days 1 & 15 of a 28-day cycle (Q2W)
- Computed Tomography (CT)-based tumour assessments were performed at screening and after every 2 cycles until progression
- NUC-3373 treatment continued until unacceptable toxicity or progressive disease

Safety

RESULTS

Investigator decision

Unacceptable toxicity

AEs

Other

- NUC-3373 has an encouraging safety profile
- 10 patients experienced Grade 3 events related to NUC-3373 (Part I, n=8; Part II, n=2)
- No Grade 4 events were related to NUC-3373
- No NUC-3373 related deaths

Primary reasons for

discontinuation

Progressive disease (RECIST v1.1)

Withdrawal of consent (patient choice)

Part I, n (%)

(n=46)

29 (63)

7 (15)

3 (7)

2 (4)

1 (2)

4 (9)

Part II, n (%)

(n=16)

15 (94)


1 (6)

- G3 transaminitis (n=2), 500 mg/m², 1875 mg/m² • G2 headache (n=1), 3250 mg/m² • G3 hypotension (n=1) 3250 mg/m²
- 4 Dose Limiting Toxicities (DLTs) in 4 patients • RP2D for NUC-3373 monotherapy was 2500 mg/m²
- given Q1W by ≤4 hour I.V. infusion

Safety event	Part I – Q1W, n (%) (n=43 patients)							RP2D		Part II – Q2W, n (%) (n=16 patients)		
	125 mg/m ² (n=3)	250 mg/m ² (n=6)	500 mg/m ² (n=8)	750 mg/m ² (n=4)	1125 mg/m ² (n=3)	1500 mg/m ² (n=3)	1875 mg/m ² (n=6)	2500 mg/m² (n=6)	3250 mg/m ² (n=4)	1500 mg/m ² (n=4)	1875 mg/m ² (n=6)	2500 mg/m ² (n=6)
SAE	0	3	4	2	1	0	2	1	2	3	1	3
Any AE (inc. SAEs)	3	6	8	4	3	3	6	6	4	4	6	6
G3/4 AEs	0	3	2	2	3	0	3	4	2	3	1	4
Treatment Related AE (any grade)	3	5	7	4	3	3	6	5	4	4	5	4
Treatment Related AE (Grade ≥3)	0	0	1	0	2	0	2	1	2	1	1	0
AE/SAEs requiring treatment discontinuation	0	3	2	0	0	0	0	0	2	0	0	0
DLTs			1				1		2			

4,000

Pharmacokinetics



Dose proportional increase of NUC-3373 AUC with dose

- Dose proportional increase in NUC-3373 C_{max} and AUC • Long plasma half-life (6-14 hours)¹⁰ compared to 5-FU (8-14 mins)
- Intracellular FUDR-MP levels increase in a dose proportional manner and are substantially higher (~300 times) compared to those reported for 5-FU¹¹

Patients (n=19) dosed at 500 - 3250mg/m²

Pavlina Spiliopoulou¹, Farasat Kazmi², Francesca Aroldi², Jill Graham¹, Lisa Jane Rodgers¹, Jane Holmes³, Thomas Holmes⁴, Simon Lord², Gareth Veal⁵, Cathy Qi³, David Harrison⁶; Vicky Coyle⁷, T.R. Jeffry Evans¹, Sarah P Blagden² (1) Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

- (2) Early Phase Trials Unit, University of Oxford, Oxford, United Kingdom
- (3) Centre for Statistics in Medicine and Oxford Clinical Trials Research Unit (OCTRU), Oxford, United Kingdom
- (4) Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, United Kingdom (5) Translational and Clinical Research Institute, University of Newcastle, Newcastle upon Tyne, United Kingdom
 - (6) School of Medicine, St Andrews, United Kingdom
 - (7) Patrick Johnston Centre for Cancer Research, Queens University, Belfast, United Kingdom

ITT population

• 62 patients: Part I (n=46); Part II (n=16)

Safety evaluable population


- 59 patients were dosed with NUC-3373 Part I (n=43)
- Part II (n=16)
- Median age 59 years (range 20-77)

Tumour types

• CRC (28), Oesphago-gastric (6), Pancreatic (4), Cervical (2), Other (22) • Median prior therapies 3 (range 0-11)

Efficacy

Part I: SD, n=12 (26%)
Part II: SD, n=3 (19%)



Patient case studies

- 2) FOLFIRI: for metastatic disease
- 3) CAPOX: progressed within 2 months

- **PFS:** 9 months Dose: 1500 mg/m² Q1W

CONCLUSIONS

- 5-FU pre-treated patients

- Phase lb/II; NCT03428958)



oster Number: 549 NCT027232 Email: sarah.blagden@oncology.ox.ac.u

• Clinical responses were observed with best response of durable stable disease (SD)

Dose: 1500 mg/m² Q2W

PFS: 11 months **Dose:** 1125 mg/m² Q1W

NUC-3373 is a TS inhibitor designed to overcome key cancer resistance mechanisms associated with 5-FU NUC-3373 is efficiently converted into active anti-cancer metabolite (FUDR-MP) NUC-3373 shows a favourable safety profile with encouraging signs of anti-cancer activity; including in

Recommended Phase 2 Dose of NUC-3373 monotherapy is 2500mg/m² Q1W NUC-3373 is currently being investigated in combination with agents commonly used in CRC (NuTide:302